|Page (1) of 1 - 01/12/18||email article||print page|
Vivos Completes Planned Dosing Schedule for Feline Sarcoma Program(January 12, 2018)
Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has completed its planned dosing schedule to determine the effectiveness of using the Company’s proprietary RadioGel™ therapy to treat feline sarcoma.
An initial study of two cats was completed in September 2017 at Washington State University (WSU). The results of that study indicated RadioGel performed as designed, confirming objective response (destruction of tumor tissue) without any negative or detrimental side-effects.
Subsequently, an additional three cats with advanced cases of sarcoma were treated, two in December 2017 and one in January 2018. As planned, the additional treatment program was completed at higher radiation doses to optimize levels for therapy.
Dosimetry calculations show that lethal doses to the cancer cells will occur over the first ten days, after which, less than 5% of the radiation will remain in the animals. It will take approximately three months for the biopsy and follow-up analysis to further confirm the effectiveness of the therapy.
The final report from these studies will be shared with VCA as part of the Company’s continuing discussions about a business relationship in private veterinarian clinics.
The next step will be to generate data on the treatment of canine sarcoma at the University of Missouri. These data will also be shared with the private clinic consortiums and with the FDA as part of the Company’s pre-clinical testing for the use of RadioGel in humans.
Mike Korenko, CEO of Vivos, stated, “We want to thank our shareholders for the continued support and patience as we execute methodically on the plan we outlined in the fall. A disciplined approach is the best way to succeed in this highly regulated environment, and we continue to make meaningful steps forward toward our goals.”
About Vivos Inc. (OTC: RDGL)
The strategic market sector of RDGL is isotope applications. Currently, the Company is engaged in the
development of RadioGelTM, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.
The Company is engaging the FDA for permission to use RadioGelTM for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of RDGL is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. RDGL is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGelTM to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGelTM in other countries.
RadioGelTM is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.
RadioGelTM also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
We have changed our email and website to reflect our focus on RadioGelTM. Please visit our website located at www.radiogel.com, which contains a direct link to recent presentations and interviews at https://www.redchip.com/company/Biotech/ADMD/376/admd.
CONTACT: CONTACT:Vivos Inc.Michael K. Korenko, President & [email protected]